Is Vertex Pharmaceuticals (VRTX) Cheap Following Its Raised 2026 Revenue Guidance?
Vertex Pharmaceuticals (VRTX) lifted its full year 2026 revenue guidance after citing continued demand in cystic fibrosis treatments and broader uptake in sickle cell disease, beta thalassemia, and acute pain therapies.
See our latest analysis for Vertex Pharmaceuticals.
The guidance upgrade comes after a strong run in Vertex Pharmaceuticals stock, with a 30 day share price return of 15.97% and a 90 day share price return of 26.13%. The 1 year total shareholder return of 38.70% and 5 year total shareholder return of 174.13% point to momentum that has been building rather than fading.
If this kind of performance has your attention, it could be a good moment to broaden your watchlist and check out 41 healthcare AI stocks
After a move like this, the real tension is between the price you see on Vertex Pharmaceuticals and the wide gap to some fair value estimates. How much of that spread still looks reasonable on today’s numbers?
Most Popular Narrative: 2% Undervalued
The most followed narrative on Vertex Pharmaceuticals values the stock at a fair value of $558.68 compared with the last close at $548.05, which implies only a modest gap and a valuation that rests heavily on how reliable the long term growth story looks from here.
Vertex's pipeline diversification, including programs in pain, kidney, and type 1 diabetes, leverages global advances in genomic and gene-editing technologies, positioning the company to capture long-term growth from accelerating personalized and precision medicine adoption, supporting both revenue and long-term margin expansion.
Want to see what sits underneath that pipeline story and valuation gap? The narrative focuses on steady revenue expansion, margin lift and a future earnings multiple that assumes Vertex Pharmaceuticals keeps compounding at scale.
Result: Fair Value of $558.68 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Vertex Pharmaceuticals still faces two clear swing factors: heavy reliance on cystic fibrosis therapies and uncertain outcomes for high cost, late stage pipeline programs.
Find out about the key risks to this Vertex Pharmaceuticals narrative.
Another View on Vertex Pharmaceuticals Valuation
The first narrative values Vertex Pharmaceuticals at $558.68 using future earnings and a P/E based approach, which points to only a small discount to the current $548.05 share price. However, the stock currently trades on a P/E of 31.5x, compared with 17.4x for the wider US Biotechs industry and a fair ratio of 28.5x. That gap suggests investors are already paying a premium, so the question is whether you see that as justified by quality and growth, or as extra valuation risk if expectations cool.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Feeling encouraged by the tone around Vertex Pharmaceuticals and its outlook for rewards? Act quickly and review the factors investors are most optimistic about in the 3 key rewards.
Looking for more investment ideas beyond Vertex Pharmaceuticals?
If Vertex Pharmaceuticals has sharpened your focus on quality, do not stop here. Broaden your opportunity set and let data driven stock ideas work harder for you.
- Target reliable compounding potential by reviewing companies that feature strong cash flows and valuations in the 48 high quality undervalued stocks.
- Prioritise resilience by checking companies that appear in the 78 resilient stocks with low risk scores so you can emphasise stability when markets turn choppy.
- Spot potential early stage opportunities by scanning the screener containing 19 high quality undiscovered gems before they land on everyone else's radar.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com